THE SOLUTE TRANSPORTER OCTN1/SLC22A4 AFFECTS DISEASE SEVERITY AND RESPONSE TO INFLIXIMAB IN EXPERIMENTAL COLITIS: ROLE OF GUT MICROBIOTA AND IMMUNE MODULATION
Letizia Masi 1
Federica Del Chierico 2
Valentina Petito 2
Valerio Baldelli 2
Pierluigi Puca 3
Maria Cristina Giustiniani 4
Marco Fidaleo 5
Ivana Palucci 6, 7
Loris Riccardo Lopetuso 1, 8
Maria Emiliana Caristo 9
Lorenza Putignani 10
Antonio Gasbarrini 1, 11
Giovambattista Pani 11
Franco Scaldaferri 1, 11
1 Department of Medical and Surgical Sciences, IBD Unit, Center for Diseases of Digestive System (CeMAD), Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
2 Immunology, Rheumatology and Infectious Diseases Research Area, Unit of Human Microbiome, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
3 Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, Italy
4 Institute of Pathological Anatomy, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy
5 Department of Biology and Biotechnologies Charles Darwin, Università La Sapienza, Rome, Italy
6 Department of Basic Biotechnological Sciences, Intensive and Perioperative Clinics, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy
7 Institute of Microbiology, Catholic University of the Sacred Heart, Rome, Italy
8 Department of Medicine and Ageing Sciences, “G. d’Annunzio” University of Chi
9 Cen.Ri.S Policlinico Gemelli UNICATT, Rome, Italy
10 Unit of Microbiology and Diagnostic Immunology, Unit of Microbiomics and Immunology, Rheumatology and Infectious Diseases Research Area, Unit of Human Microbiome, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
11 Department of Translational Medicine and Surgery, Catholic University of the
Topic
IBD
Session
PP 05 IBD (Posters)
Conference
UEG Week 2023
Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]